NOVOZYMES A/S SPONS.ADR 1 (NZM) - Total Liabilities
Based on the latest financial reports, NOVOZYMES A/S SPONS.ADR 1 (NZM) has total liabilities worth €5.60 Billion EUR (≈ $6.55 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of NOVOZYMES A/S SPONS.ADR 1 to track the company's year-over-year net asset growth rate.
NOVOZYMES A/S SPONS.ADR 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how NOVOZYMES A/S SPONS.ADR 1's total liabilities have evolved over time, based on quarterly financial data.
NOVOZYMES A/S SPONS.ADR 1 Competitors by Total Liabilities
The table below lists competitors of NOVOZYMES A/S SPONS.ADR 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NATURGY ENERGY ADR1/5/E01
F:GANA
|
Germany | €30.92 Billion |
|
American Water Works
NYSE:AWK
|
USA | $23.84 Billion |
|
Willis Towers Watson PLC
NASDAQ:WTW
|
USA | $21.48 Billion |
|
ABN Amro Group NV
AS:ABN
|
Netherlands | €386.17 Billion |
|
Epiroc AB (publ)
ST:EPI-A
|
Sweden | Skr38.10 Billion |
|
XPO Logistics Inc
NYSE:XPO
|
USA | $6.33 Billion |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
USA | $1.59 Billion |
|
Repsol S.A
F:REPA
|
Germany | €36.33 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down NOVOZYMES A/S SPONS.ADR 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of NOVOZYMES A/S SPONS.ADR 1.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NOVOZYMES A/S SPONS.ADR 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
The table below shows the annual total liabilities of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.49 Billion ≈ $6.42 Billion |
+36.68% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
+113.38% |
| 2023-12-31 | €1.88 Billion ≈ $2.20 Billion |
+2.04% |
| 2022-12-31 | €1.85 Billion ≈ $2.16 Billion |
+9.31% |
| 2021-12-31 | €1.69 Billion ≈ $1.97 Billion |
-- |
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more